Evidence-based urology in practice: composite endpoints.
Lavallée
Luke T
LT
Division of Urology, University of Ottawa, Ottawa, ON, Canada.
Dahm
Philipp
P
Breau
Rodney H
RH
D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D023381:Endpoint Determination; D019317:Evidence-Based Medicine; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D053448:Prostatism / Q000188:drug therapy* / Q000209:etiology; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D018120:Finasteride; D017292:Doxazosin